COGT Stock Forecast & Price Target

Cogent Biosciences is positioned well because FDA acceptance of three bezuclastinib NDAs creates a rare, near-term multi-catalyst setup with PDUFAs on November 30, 2026, December 30, 2026, and June 29, 2027, while no advisory committee is currently planned for AdvSM. Clinical data from APEX and PEAK support the thesis, with 54% to 65% ORR in AdvSM, 81% pure pathological response, 12-month PFS/OS of 79%/87%, and in 2L GIST a 50% reduction in progression or death versus sunitinib plus a 46% ORR. Fundamentally, the company combines a differentiated KIT franchise, launch readiness, and $865.9M pro forma cash that provides runway into late 2028, supporting execution across three potential commercial indications.

Cogent Biosciences is viewed negatively because AdvSM is already a competitive market, with Sanofi’s Ayvakit established as the standard of care and physicians having substantial experience with an effective KIT inhibitor. The company may need meaningful commercial investment to win utilization, which raises execution risk and could delay meaningful uptake even if CGT9486 is approved. Near-term downside is driven by the possibility of poorer-than-expected clinical results, longer approval timelines or no approval, stronger competitors, regulatory and commercial setbacks, lower sales than expected, and dilutive financing.